Head and Neck Squamous Cell Carcinoma (HNSCC)Phase 2ORIONNCT07888816
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers
A Phase 2 study testing Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy in people with Head and Neck Squamous Cell Carcinoma (HNSCC), run by University Health Network, Toronto at 1 site in Canada.
Trial summary
The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- What is being tested?
- Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteCanada
- Study dates
- 1 Nov 2026to 30 Sep 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Estimated life expectancy ≥ 6 months
- Histologically confirmed mucosal head and neck squamous cell carcinoma (HNSCC) of the nasal cavity, nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, or other mucosal site
- Disease not amenable to curative-intent local therapy
- Radiographically evident disease at the planned pulsed RT target(s)
Show all 15Show fewer
- Patient must meet criteria for one of three cohorts: Cohort 1: Newly diagnosed locoregionally advanced or metastatic HNSCC unfit for curative-intent therapy, Cohort 2: Recurrent and/or metastatic disease after prior local therapy, Cohort 3: Oligoprogression (≤5 sites) on immunotherapy ± chemotherapy
- Candidate for immunotherapy as determined by medical oncologist
- For chemotherapy-eligible patients, candidate for platinum-based chemotherapy
- Planned RT target(s) within the head and neck region amenable to delivery on Varian Ethos with online adaptive replanning for at least one site.
- For patients with RT target(s) outside head and neck, they may be treated with online or offline adapted pulsed RT
- Adequate organ function for initiation of immunotherapy as determined by the medical oncologist.
- Women of childbearing potential must have a negative serum pregnancy test within 7 days of fifirst study treatment
- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in English. Inability (lack of comprehension in English, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
- Written informed consent obtained prior to any study-specific procedures.
Who cannot join
- Two or more prior courses of radiotherapy to a planned re-irradiation site
- Laryngeal local recurrence requiring RT after prior ≥ 50 Gy to the larynx
- Previous RT to the target lesion(s) completed within 6 months before enrollment
- Uncontrolled brain metastases (controlled/treated brain metastases are permitted)
- Active second malignancy requiring treatment, with the exception of localized cutaneous malignancy or in-situ disease
- Head and neck target not amenable to RT delivery on Varian Ethos with online adaptive replanning
Show all 11Show fewer
- Contraindication to immune checkpoint inhibitors, including: Active autoimmune disease requiring systemic immunosuppressive therapy, Prior grade ≥ 3 immune-related adverse event attributable to prior ICI therapy, Active or recent (within 6 months) interstitial lung disease or pneumonitis requiring corticosteroids
- Hypersensitivity to pembrolizumab
- Pregnancy or breastfeeding
- Inability to lie supine for online adaptive radiotherapy delivery
- Any uncontrolled medical condition that, in the opinion of the investigator, would compromise patient safety or study compliance
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Princess Margaret Cancer Center
Toronto, Ontario, M5A2M9
Nauman Malik, nauman.malik@uhn.ca
About this study
The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC). Participants will receive pulsed adaptive radiotherapy delivered in 3 to 5 treatment courses approximately 10 days apart, alongside standard-of-care pembrolizumab with or without chemotherapy. Using advanced imaging and adaptive treatment planning, radiotherapy will be tailored to changes in tumor size and surrounding tissues throughout treatment. The study will assess safety, disease control, progression-free survival, quality of life, and biological markers of treatment response. Researchers hypothesize that combining pulsed radiotherapy with systemic therapy will improve 12-month progression-free survival from 17% to 32%, potentially leading to improved outcomes for patients with advanced head and neck cancer.
- Being tested
- Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapyCombination product
The primary tumor in the head and neck region, or dominant metastatic site, will be treated with pulsed RT consisting of 8 Gy pulses delivered every 10-11 days for a total of 5 pulses, delivered exclusively with online adaptive radiotherapy on the Varian Ethos platform. Concomitantly, patients will be treated with the standard systemic treatment with pembrolizumab with or without chemotherapy.
| Study group | Role | What they receive |
|---|---|---|
| Pulsed Adaptive Radiotherapy Plus Pembrolizumab ± Chemotherapy | Experimental | Not described Receives: Combination Product: Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
12-Month Progression-Free Survival
12-month progression-free survival will be estimated using the Kaplan-Meier method. The proportion of patients progression-free at 12 months will be compared to the historical benchmark of 17%. The study will be considered positive if the lower bound of the 95% confidence interval exceeds 17%.
Measured: 12 months
Secondary outcomes (13)
12-Month Modified Progression-Free Survival (mPFS)
Modified progression-free survival is defined as the time from study enrollment to disease progression that is no longer amenable to local salvage radiotherapy or death from any cause, whichever occurs first.
Measured: 12 months
Treatment-Related Adverse Events
The incidence, severity, and type of acute and late treatment-related adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0.
Measured: 12 Months
Changes in Patient-Reported Quality of Life
Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) with higher scores indicating better quality of life. Changes from baseline will be assessed at each study time point.
Measured: 12 Months
Changes in Patient-Reported Quality of Life and Functional Outcomes
Assessed using the EORTC Head and Neck Cancer Module (QLQ-H\&N43). Scores range from 0 to 100 scale where for the functional scales, higher scores indicate better functioning. For symptom scales and symptom items, higher scores indicate greater symptom burden or worse symptoms. Changes from baseline over the study period will be evaluated.
Measured: 12 Months
Swallowing Function
Swallowing function will be assessed using the Functional Oral Intake Scale (FOIS), where scores range from 1 to 7, where 1 indicates no oral intake (nothing by mouth) and 7 indicates a full oral diet with no restrictions. Higher scores indicate better oral intake and swallowing function. Changes from baseline over the study period will be evaluated.
Measured: 12 Months
Changes in Patient-Reported Quality of Life and Functional Outcomes
Assessed using the Performance Status Scale for Head and Neck Cancer (PSS-HN), which evaluates three domains: Normalcy of Diet, Eating in Public, and Understandability of Speech. Each domain is scored separately on a scale from 0 to 100, with higher scores indicating better function and less impairment. Changes from baseline over the study period will be evaluated.
Measured: 12 Months
Median Progression-Free Survival (PFS)
Estimated using the Kaplan-Meier method with 95% confidence intervals
Measured: 12 months
Median Overall Survival (OS)
Estimated using the Kaplan-Meier method with 95% confidence intervals
Measured: 12 months
Objective Response Rate (ORR)
Reported as a proportion with 95% confidence intervals
Measured: 12 months
Duration of Response (DoR)
Estimated using the Kaplan-Meier method with 95% confidence intervals
Measured: 12 months
Time to Next Systemic Therapy
Estimated using the Kaplan-Meier method, with patients censored at last contact if they have not initiated next-line therapy
Measured: 12 months
Health Economic Impact
Health economic outcomes will be assessed through measures of healthcare resource utilization (Total treatment visits, imaging utilization, resource utilization) compared to historical conventional palliative RT cohorts.
Measured: 12 months
Financial Toxicity
Patient-reported financial toxicity using Financial Toxicity Questionnaire, with higher scores indicating less financial distress (better financial well-being) and lower scores indicating greater financial toxicity (worse financial burden).
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion30 Sep 2029 (estimated)
- Study completion30 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head and Neck Squamous Cell Carcinoma (HNSCC)Studies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07888816
- Sponsor's protocol ID
- 26-5660
- Acronym
- ORION
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers
- ClinicalTrials.gov ID
- NCT07888816
- Acronym / sponsor ID
- ORION / 26-5660
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 30 Sep 2029 (estimated)
- Study completion
- 30 Sep 2029 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC). Participants will receive pulsed adaptive radiotherapy delivered in 3 to 5 treatment courses approximately 10 days apart, alongside standard-of-care pembrolizumab with or without chemotherapy. Using advanced imaging and adaptive treatment planning, radiotherapy will be tailored to changes in tumor size and surrounding tissues throughout treatment. The study will assess safety, disease control, progression-free survival, quality of life, and biological markers of treatment response. Researchers hypothesize that combining pulsed radiotherapy with systemic therapy will improve 12-month progression-free survival from 17% to 32%, potentially leading to improved outcomes for patients with advanced head and neck cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pulsed Adaptive Radiotherapy Plus Pembrolizumab ± Chemotherapy | Experimental | Combination Product: Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Estimated life expectancy ≥ 6 months
- Histologically confirmed mucosal head and neck squamous cell carcinoma (HNSCC) of the nasal cavity, nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, or other mucosal site
- Disease not amenable to curative-intent local therapy
Key exclusion criteria (11 listed)
- Two or more prior courses of radiotherapy to a planned re-irradiation site
- Laryngeal local recurrence requiring RT after prior ≥ 50 Gy to the larynx
- Previous RT to the target lesion(s) completed within 6 months before enrollment
- Uncontrolled brain metastases (controlled/treated brain metastases are permitted)
- Active second malignancy requiring treatment, with the exception of localized cutaneous malignancy or in-situ disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapyThe primary tumor in the head and neck region, or dominant metastatic site, will be treated with pulsed RT consisting of 8 Gy pulses delivered every 10-11 days for a total of 5 pulses, delivered exclusively with online adaptive radiotherapy on the Varian Ethos platform. Concomitantly, patients will be treated with the standard systemic treatment with pembrolizumab with or without chemotherapy. | Combination product | Pulsed Adaptive Radiotherapy Plus Pembrolizumab ± Chemotherapy |
Primary outcome
12-Month Progression-Free Survival
Time frame: 12 months
12-month progression-free survival will be estimated using the Kaplan-Meier method. The proportion of patients progression-free at 12 months will be compared to the historical benchmark of 17%. The study will be considered positive if the lower bound of the 95% confidence interval exceeds 17%.
13 secondary outcomes
12-Month Modified Progression-Free Survival (mPFS)
Time frame: 12 months
Treatment-Related Adverse Events
Time frame: 12 Months
Changes in Patient-Reported Quality of Life
Time frame: 12 Months
Changes in Patient-Reported Quality of Life and Functional Outcomes
Time frame: 12 Months
Swallowing Function
Time frame: 12 Months
Changes in Patient-Reported Quality of Life and Functional Outcomes
Time frame: 12 Months
Median Progression-Free Survival (PFS)
Time frame: 12 months
Median Overall Survival (OS)
Time frame: 12 months
Objective Response Rate (ORR)
Time frame: 12 months
Duration of Response (DoR)
Time frame: 12 months
Time to Next Systemic Therapy
Time frame: 12 months
Health Economic Impact
Time frame: 12 months
Financial Toxicity
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
Related trials for Head and Neck Squamous Cell Carcinoma (HNSCC)
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingPhase 2
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
RecruitingPhase 1/2
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy in people with Head and Neck Squamous Cell Carcinoma (HNSCC), run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
12-Month Progression-Free Survival (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.